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Perineural invasion (PNI) is a tropism of tumor cells
for nerve bundles located in the surrounding stroma.
It is a pathological feature observed in certain tumors,
referred to as neurotropic malignancies, that severely
limits the ability to establish local control of disease
and results in pain, recurrent growth, and distant
metastases. Despite the importance of PNI as a prog-
nostic indicator, its biological mechanisms are poorly
understood. The semaphorins and their receptors,
the plexins, compose a family of proteins originally
shown to be important in nerve cell adhesion, axon
migration, and proper central nervous system devel-
opment. Emerging evidence has demonstrated that
these factors are expressed in tissues outside of the
nervous system and represent a widespread signal
transduction system that is involved in the regulation
of motility and adhesion in different cell types. We
believe that the plexins and semaphorins, which are
strongly expressed in both axons and many carcino-
mas, play a role in PNI. In this study, we show that
plexin-B1 is overexpressed in tissues and cell lines
from neurotropic malignancies and is attracted to
nerves that express its ligand, semaphorin 4D, in a
Rho/Rho kinase-dependent manner. We also demon-
strate that nerves are attracted to tumors through this
same system of proteins, suggesting that both
plexin-B1 and semaphorin 4D are important in the
promotion of PNI. (Am J Pathol 2012, 180:xxx; DOI:
10.1016/j.ajpath.2011.12.009)
Many carcinomas display perineural invasion (PNI), a
tropism of tumor cells for surrounding nerve bundles. PNI
promotes cancer cell survival and severely limits the abil-
ity to establish local control of disease. As a result, these
tumors can exhibit pain and persistent growth, with a long
clinical course and late onset of metastases, a pattern
that has been observed in neurotropic tumor types, such
as prostate and pancreatic cancers,1 head and neck
squamous cell carcinoma (HNSCC),2 and the salivary
gland malignancies adenoid cystic carcinoma (ACC)3
and polymorphous low-grade adenocarcinoma (PLGA).4
PNI is an independent predictor of poor outcome in neu-
rotropic malignancies.4–6
The semaphorins are a large family of proteins char-
acterized by cysteine-rich semaphorin domains originally
identified based on their ability to provide attractive and
repulsive axon guidance cues during development.7 Re-
cently, semaphorins have been identified in a variety of
adult and embryonic tissues, in which they regulate de-
velopment of the lungs,8 the heart and vasculature,9
branching morphogenesis in epithelium,10 angiogene-
sis,11,12 and proliferation and activation of lympho-
cytes,13,14 suggesting that they are important proteins
that compose a system controlling migratory events in
numerous tissues and cell types. The main functional
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receptors for semaphorins are a family of proteins known
as the plexins.15 The nature of the signals generated by
semaphorin-plexin binding is still being deciphered, but
there is a great deal of evidence that it impinges on the
cytoskeleton and affects cell motility by acting through
G-protein–signaling pathways.11,16–18
Herein, we demonstrate that cell lines and tissues de-
rived from neurotropic tumors express high levels of
plexin-B1 compared with nontransformed controls or tu-
mors that are not known for PNI, whereas nerves express
its ligand, semaphorin 4D (Sema4D). The prostate can-
cer cell lines PC3 and Du-145 migrate toward nerve cell
lines expressing Sema4D, a response abrogated when
plexin-B1 or Sema4D is knocked down through RNA in-
terference (RNAi) or when signaling of RhoA and its
downstream effector Rho kinase (ROK) is inhibited. PC3
and Du-145 also exhibit a robust response in an invasion
assay toward dorsal root ganglia (DRG) when using wild-
type, but not Sema4D knockout, nerve tissue as the che-
moattractant. LnCAPs, which are poor expressers of
plexin-B1, fail to migrate toward nerve lines or tissues
regardless of Sema4D status. Finally, we noted greater
PNI in an in vivo tumor xenograft model by neurotropic
malignant cells with functional plexin-B1 compared with
that seen in cells in which plexin-B1 was silenced through
RNAi; this could enhance neural spread in LnCAPs by
overexpressing plexin-B1 in the grafted cells.
Emerging models of PNI strongly suggest that interac-
tions between tumor cells and nerves induce tumor cell
migration and stimulate nerve growth or axonogenesis.
Herein, we show that nerve cell lines migrate toward PC3
cells and exhibit extended nerve processes in a Sema4D/
plexin-B1–dependent manner, a response also blocked
by Rho/ROK inhibition. We observed neurite outgrowth in
a co-culture of PC3 cells with wild-type DRG, but not from
DRG harvested from plexin-B1 knockout mice or in which
Sema4D was silenced in the PC3 cells. Confirming these
findings, we noted greater nerve density in biopsy spec-
imens of HNSCC xenografts expressing Sema4D com-
pared with tumors from cells in which Sema4D was si-
lenced. In addition, we noted higher nerve densities in
neurotropic tumors in general compared with nonneu-
rotropic tumors or normal control tissues, indicating that
the process of PNI involves enhanced nerve growth.
Taken together, these results show that the plexins and
semaphorins, which are strongly expressed in both ax-
ons and many carcinomas, play a significant role in PNI.
Materials and Methods
Cell Culture
All cell lines were grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine
serum (FBS) and 100 U/mL penicillin/streptomycin/am-
photericin B (Sigma, St Louis, MO), with the following
exceptions: immortalized normal oral keratinocytes were
cultured in defined keratinocyte media (Gibco, Invitro-
gen, Carlsbad, CA). The prostate cancer epithelial cell
lines PC3, Du-145, and LnCAP were cultured in RPMI
1640 media (Cellgro, Manassas, VA). The nontrans-
formed human pancreatic cell line hTERT-HPNE was cul-
tured in 75% DMEM and 25% Medium M3 Base (Incell
Corp, San Antonio, TX), supplemented with 5% FBS, 10
ng/mL human recombinant epidermal growth factor, 5.5
mmol/L D-glucose, and 750 ng/mL puromycin. Human
pancreatic carcinoma cells were cultured in a 1:1 mixture
of DMEM and Ham’s F12 medium (ATCC, Manassas,
VA), supplemented with 5% FBS, 0.002 mg/mL insulin,
0.005 mg/mL transferrin, 40 ng/mL hydrocortisone, and
10 ng/mL epidermal growth factor. Capan-1 cells were
cultured in Iscove’s modified Dulbecco’s medium
(ATCC), supplemented with 20% FBS and 100 U/mL pen-
icillin/streptomycin/amphotericin B (Sigma).
Immunoblot Analysis
Cells were lysed in buffer (50 mmol/L Tris-HCl, pH 7.4;
150 mmol/L NaCl; and 1% Nonidet P-40), supplemented
with protease inhibitors (0.5 mmol/L phenylmethylsulfonyl
fluoride and 1 !L/mL aprotinin and leupeptin; Sigma) and
phosphatase inhibitors (2 mmol/L NaF and 0.5 mmol/L
sodium orthovanadate, Sigma) for 15 minutes at 4°C.
After centrifugation, protein concentrations were mea-
sured using the Bio-Rad assay (Bio-Rad, Hercules, CA),
subjected to SDS-PAGE, and transferred onto a polyvi-
nylidene fluoride membrane (Immobilon P; Millipore, Bil-
lerica, MA). The membranes were then incubated with
the following antibodies: Sema4D (BD Transduction
Labs, BD Biosciences, Palo Alto, CA), plexin-B1 (Santa
Cruz A8, Santa Cruz, CA), and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH; Sigma). Proteins were
detected using the enhanced chemiluminescence sys-
tem (Pierce, Thermo Fisher Scientific, Rockford, IL).
Immunohistochemistry Findings
Slides were hydrated through graded alcohols and incu-
bated in 3% hydrogen peroxide for 10 minutes to quench
the endogenous peroxidase. The sections were then in-
cubated in blocking solution [2% bovine serum albumin
(BSA)] for 1 hour at room temperature, followed by treat-
ment with anti-Sema4D antibody (1:50 dilution; BD Trans-
duction Labs), anti-plexin-B1 antibody (Santa Cruz A8,
1:10 dilution), or neurofilament protein (1:100 dilution;
Cell Signaling, Danvers, MA), where indicated, overnight
at 4°C. After washing with PBS, the slides were incubated
with the biotinylated secondary antibody (1:400 dilution;
Vector Laboratories, Burlingame, CA) for 1 hour, followed
by the ABC complex (Vector Stain Elite, ABC kit; Vector
Laboratories) for 30 minutes or with streptavidin peroxi-
dase (LSAB!HRP kit; Dako, Carpinteria, CA) at room
temperature. The slides were developed in 3,3-diamino-
benzidine (DAB Substrate kit for peroxidase; Vector Lab-
oratories) and counterstained with hematoxylin. Images
were taken using an Aperio Scanscope (Aperio Technol-
ogies, Vista, CA). To confirm staining, lymphocytes,
which express high levels of Sema4D, were used as
internal controls for this protein, whereas nerves were
used as internal controls for expression of plexin-B1. For
measuring protein expression, a scale of 0 to 3 was used
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to assess the number of positively stained cells and the
staining intensity, with the results added together to yield
a final staining score.
shRNA and Lentivirus Infections
The short-hairpin RNA (shRNA) sequences for human
Sema4D and plexin-B1 were obtained from Cold Spring
Harbor Laboratory’s RNAi library (RNAi Central, http://
cancan.cshl.edu/RNAi_central/RNAi.cgi?type"shRNA, last
accessed December 15, 2011).19,20 The sequences
used as PCR templates for Sema4D shRNA have been
previously reported.21 The sequence used for plexin-B1
shRNA was as follows: 5=-TGCTGTTGACAGTGAGC-
GCGCCCAGTATGTGGCCAAGAACTAGTGAAGCCACA-
GATGTAGTTCTTGGCCACATACTGGGCATGCCT-
ACTGCCTCGGA-3=. Oligos were synthesized (Invitro-
gen), and the resulting PCR products were cloned into
pWPI GW, a Gateway-compatible CSCG-based lentiviral
destination vector, as previously described.21–23 Viral
stocks were prepared and infections were performed as
previously reported.21,24,25
Migration Assays
Serum-free medium containing the indicated cell type or
chemoattractant was placed in the bottom well of a Boyden
chamber, whereas serum-free medium containing the mi-
grating cells, with or without 10 !mol/L of the ROK inhibitor
fasudil (Calbiochem, Darmstadt, Germany), where indi-
cated, was added to the top chamber. The two chambers
were separated by a polyvinylpyrrolidone membrane (8 !
pore size, Osmonics; GE Water Technologies, Trevose,
PA), and the migration assay was performed as de-
scribed.11 Cell migration was expressed as staining inten-
sity of scanned migration membranes relative to the nega-
tive control wells. Each experiment was performed in
triplicate, and the average and SD were calculated.
Invasion Assays
DRG from the cervical, thoracic, and lumbar areas of 4- to
7-week-old control and Sema4D knockout mice were dis-
sected from donor animals, as previously reported.26
Cultrex basement membrane material (100 !L; Trevigen,
Gaithersburg, MD) was placed into the upper chamber of
24-well transwell inserts (Millipore) and allowed to polym-
erize. DRG were placed in the lower chamber, and 1
million PC3, Du-145, or LnCAP cells in DMEM containing
1% FBS were added to the coated insert and incubated
for 6 hours at 37°C in a humidified atmosphere of 5%
CO2. Inserts were stained and processed for cell content,
according to the manufacturer’s instructions.
Neurite Outgrowth Assay
DRG were isolated from wild-type and plexin-B1 knock-
out mice, as previously reported,26 placed on a coverslip
under sterile conditions in 20 !L of Cultrex (Trevigen),27
and co-cultured with control-infected PC3 cells or PC3
infected with lentivirus coding for Sema4D shRNA. DRG
and PC3 cells were maintained at 37°C in a humidified
atmosphere of 5% CO2. The number of neurites was
counted along the entire DRG circumference, and im-
ages were captured using a digital SPOT camera (SPOT
Imaging Solutions, Sterling Heights, MI) attached to an
inverted Nikon phase-contrast microscope (Nikon Instru-
ments, Melville, NY) on days 1, 3, 5, 7, 9, and 11. All
experiments were performed in triplicate.
Tumor Tissues
Prostate cancer tissue arrays containing carcinoma sam-
ples and normal controls were obtained from Biomax
(Rockville, MD). Individual paraffin blocks of formalin-
fixed tissues from normal mucosa/acanthosis, basal cell
carcinoma (BCC), squamous cell carcinoma, mucoceles,
low- and high-grade mucoepidermoid carcinomas
(MECs), ACCs, and PLGAs were obtained from the De-
partment of Oncology and Diagnostic Sciences, Univer-
sity of Maryland (Baltimore, MD).
In Vivo PNI and Nerve Density Assays
A total of 2 # 106 PC3, LnCAP, HN6, or HN12 cells
infected ex vivo with control virus or virus coding for
plexin-B1 shRNA, plexin-B1, or Sema4D shRNA, where
indicated, were resuspended in 250 !L of serum-free
DMEM with an equal volume of Cultrex basement mem-
brane extract (BME; Trevigen) and injected s.c. into the
flanks of nude mice.28 The mice were sacrificed, and the
tumor masses were removed, fixed with formalin, and
processed for immunohistochemistry (IHC) for neurofila-
ment protein (Cell Signaling).
Immunofluorescence for Neurite Outgrowth on
sNF96.2 Cells
sNF96.2 cells (ATCC) transfected with TrkA-PB1, TrkA-
PB1$PDZ, and TrkA-PB1 RasGAP mutant were seeded
at 40% confluence on fibronectin (Santa Cruz Biotech-
nology, Santa Cruz, CA) coated coverslips. Cells were
grown overnight in DMEM supplemented with 5% FBS
and 100 !g/mL nerve growth factor (NGF). At the con-
clusion of the growth period, cells were stained for im-
munofluorescence. Neurons were fixed in 4% parafor-
maldehyde, permeabilized with 0.25% Triton X-100,
blocked with 2% (w/v) BSA, and incubated overnight at
4°C with anti-neurofilament antibody (Cell Signaling) di-
luted 1:100 in 1% BSA. For the secondary antibody, cells
were incubated for 1 hour at room temperature with flu-
orescein isothiocyanate–conjugated donkey anti-rabbit
antibody (Jackson ImmunoResearch Laboratories, Inc.,
Baltimore, MD), diluted 1:200 in PBS with 1% BSA, and
10 !g/mL Hoechst 33342 (Sigma). Image acquisition was
performed on a Nikon Eclipse E800 Microscope (Nikon,
Melville, NY) using a #40 objective lens. Image analysis
was performed using the Neuron J module of ImageJ
version 1.46c (NIH, Bethesda, MD), measuring the num-
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ber of cells exhibiting neurites and summing the total
neurite length in pixels.
Results
Neurotropic Tumor and Nerve Cell Lines and
Tissues Express Plexin-B1 and Sema4D
Immunoblots of cell lines derived from different neu-
rotropic malignancies revealed high levels of expression
of plexin-B1 and Sema4D in the HNSCC lines HN12 (iso-
lated from a lymph node metastasis) and HN13 (isolated
from a base of tongue cancer) but not in their corre-
sponding nontransformed controls (Figure 1A). Similar
results were observed in the human pancreatic cancer
cell lines (a primary pancreatic adenocarcinoma epithe-
lial cell line) and Capan-1 (derived from transformed pan-
creatic duct cells), when compared with HPNE (a non-
transformed human pancreatic cell immortalized with
h-TERT) (Figure 1A). We then identified the prostate cell
lines PC3 (a bone metastasis from a stage IV prostatic
adenocarcinoma) and Du-145 (derived from a brain met-
astatic deposit), which exhibit PNI in vivo, and compared
levels of Sema4D and plexin-B1 in an immunoblot with
their corresponding nontransformed control lines HPR-1
(a prostate cell line immortalized from normal human
prostate epithelial cells) and BPH-1 (a benign prostatic
hypertrophy cell line) and also with LnCAP, a line not
known for PNI.29 The results of this immunoblot demon-
strate that, as expected, PC3 and Du-145 express
higher levels of Sema4D and plexin-B1 compared with
nontransformed controls but also when compared with
the low-PNI cell line, LnCAP (Figure 1B), suggesting a
function for these proteins in PNI. The nerve cell lines
HCN-1A and sNF96.2 also express Sema4D and
plexin-B1 (Figure 1C).
We looked to confirm these findings in control and
tumor tissues. We found plexin-B1 was expressed in
most tissues we studied from tumors that are known to
exhibit PNI, including HNSCC, high-grade MEC, ACC,
PLGA (another salivary gland tumor that exhibits PNI),
and prostate carcinoma (Figure 2A). Plexin-B1 was not
expressed in their corresponding nontransformed con-
trol tissues or in tumors derived from the same sites in
the body that are not known to exhibit robust PNI,
including basal cell carcinoma, low-grade MEC, acinic
cell adenocarcinoma, and benign prostatic hypertro-
phy (BPH) (Figure 2A). Nerves express Sema4D, as
expected (Figure 2B). Quantification of tumor tissue
staining for plexin-B1 in high-PNI tumors, determined
by the number of positive cells and staining intensity, is
shown in Figure 2C by site of origin and demonstrates
that most tissues from neurotropic malignancies exhibit
moderate to strong staining for all sections examined.
Sema4D/Plexin-B1–Mediated Attraction of
Neurotropic Tumor Cells toward Nerves Is
Dependent on Activation of RhoA
To determine the effects of expression of Sema4D and
plexin-B1 on tumor cell migration toward nerves, we ex-
amined chemotaxis of PC3, infected with control lentivi-
rus or lentivirus expressing plexin-B1 shRNA, toward the
nerve cell line sNF96.2, infected with control lentivirus or
lentivirus expressing Sema4D shRNA, in a Boyden cham-
ber migration assay. PC3 cells infected with plexin-B1
shRNA-expressing lentivirus exhibited reduced levels of
plexin-B1 protein (Figure 3A), whereas sNF96.2 infected
with Sema4D shRNA expressing lentivirus exhibited
knockdown of this protein in an immunoblot (Figure 3A),
when compared with control-infected cells. PC3 migrated
toward sNF96.2 cells, except when they were expressing
lower levels of plexin-B1, when the sNF96.2 cells failed to
express Sema4D, or both (Figure 3B).
To determine the effects of expression of Sema4D and
plexin-B1 on the ability of neurotropic tumor cells to in-
vade the extracellular matrix in an attempt to reach
nearby nerves, we cultured DRG from C57BL/6 control or
Sema4D knockout mice30 in reconstituted BME and ex-
amined the response of the high-PNI prostate cell lines
PC3 and Du-145 and the low-PNI line LnCAP in an inva-
sion assay. PC3 and Du-145, which express high levels
of endogenous plexin-B1 (Figure 1B), exhibited an ap-
proximately twofold greater invasion through the BME
toward DRG harvested from wild-type mice compared
with DRG from Sema4D knockouts, which exhibited inva-
sion rates similar to those of the negative control (Figure
3C). LnCAPs, which express low levels of plexin-B1 (Fig-
ure 1B), do not exhibit statistically significant differences
in invasion toward either wild-type or knockout DRG (Fig-
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Figure 1. Plexin-B1 and Sema4D are highly expressed in neurotropic tumor
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PAGE immunoblot for plexin-B1 and Sema4D in the HNSCC lines HN12 and
HN13 and the corresponding nontransformed control line, immortalized
normal oral keratinocytes (INOKs), and the pancreatic cancer cell lines,
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Du-145 and PC3, prostate cancer cell lines that exhibit PNI, express high
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ure 3C). Taken together, these results suggest that
Sema4D expression by nerves is important as a chemot-
actic compound for cells from neurotropic tumors ex-
pressing plexin-B1.
Plexin-B1 acts as a GTPase activating protein (GAP),
inactivating R-Ras, while simultaneously binding the Rho
GTP/GDP exchange factors (GEF) PDZ RhoGEF and leu-
kemia-associated Rho GEF and activating RhoA and its
downstream effector ROK.17,31 We have previously
shown that activation of Rho by plexin-B1 was necessary
for chemotaxis of endothelial cells toward Sema4D.11 To
determine which of these properties of plexin-B1 was
necessary for migration of neurotropic tumor cells toward
nerves, we transfected PC3 cells with myc-tagged chi-
meric receptors consisting of the extracellular portion of
the rat NGF receptor, Trk-A, fused to the transmembrane
and intracellular portion of plexin-B1,11 both wild type
and mutated, to inactivate the RasGAP function.32 We
then examined their migration in the presence of NGF,
with or without the ROK inhibitor fasudil. PC3 cells ex-
pressed both Trk-A receptors, those fused to wild-type
plexin-B1 and the RasGAP mutant, in an immunoblot
for myc (Figure 3D). PC3 cells migrated toward NGF
when expressing the wild-type or RasGAP mutant
plexin-B1 segment, compared with negative control
populations, but failed to do so in the presence of
fasudil (Figure 3E). To further examine the biological
significance as it relates to PNI, we examined che-
motaxis of PC3 toward the nerve cell line sNF96.2 in a
migration assay, in the presence or absence of fasudil.
PC3 cells migrated toward sNF96.2 cells, except when
treated with fasudil (Figure 3F). These results indicate
that Sema4D/plexin-B1–mediated cell migration is de-
pendent on the ability of plexin-B1 to activate RhoA
and ROK and not on its ability to inactivate R-Ras.
Neurotropic Tumor Cells Are Attracted to
Nerves in Vivo in a Plexin-B1–Dependent
Manner
To study the contribution of plexin-B1 in tumor cells to PNI
in vivo, we injected PC3 cells infected with control lenti-
virus or lentivirus-expressing plexin-B1 shRNA into nude
mice. After 4 weeks, tumors were removed and pro-
cessed into slides to look for invasion into nerves. We
observed frequent examples of PNI by control-infected
tumor cells but fewer instances of this phenotype in PC3
with silenced plexin-B1 (Figure 4A). Quantification of
these results is shown in Figure 4A. We then grafted the
low-PNI cell line LnCAP, control infected or infected with
virus coding for full-length plexin-B1, and looked for dif-
ferences in PNI. We observed little PNI in control-infected
cells, as expected, but could induce this response in
cells that overexpressed plexin-B1 (Figure 4B). Taken
together, these results suggest that plexin-B1 expression
is necessary for the ability of tumor cells to exhibit PNI in
the stroma.
HNSCC ACC PLGA Prostate cancer
Plexin-B1
BPH
MEC high-grade
MEC, low-grade ACA
hi
gh
-P
N
I t
um
or
s
lo
w
-P
N
I t
um
or
s/
be
ni
gn
 c
on
tro
ls
no
rm
al
 ti
ss
ue
s
BCC
mucosa salivary gland prostate
Sema4D, nerve
 
B C
A
Plexin-B1
staining
0
1-2
3-4
5-6
, 
HNSCC
9
1
2
salivary gland 
31
11
6
prostate
23
17
6
4
Figure 2. Plexin-B1 is expressed in neurotropic
tumors, whereas nerves express Sema4D. A: IHC
analysis for plexin-B1 in normal tissues, tumors
not known to exhibit PNI, or benign controls
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known for PNI (high-PNI tumors), grouped by
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of Sema4D. Original magnification, #20. C: A
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Tumors Producing Sema4D Induce
Axonogenesis through Plexin-B1
Emerging models of PNI strongly suggest that interac-
tions between tumor cells and nerves induce tumor cell
migration and stimulate nerve growth or axonogenesis.
We hypothesized that if Sema4D, produced by nerves,
could act as a chemoattractant for tumor cells expressing
plexin-B1, then production of Sema4D by tumor cells
might attract nerves expressing plexin-B1. All of the neu-
rotropic tumor cell lines we tested express Sema4D in an
immunoblot (Figure 1A), whereas low-PNI LnCAP failed
to do so (Figure 1B). Tissues from neurotropic tumors
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Figure 3. Sema4D/plexin-B1–mediated attraction of neurotropic tumor cells to-
ward nerves is dependent on activation of RhoA. A: Immunoblot analysis for
plexin-B1 and Sema4D on lysates from PC3 and sNF96.2, respectively, infected with
empty vector control lentivirus (C) or virus coding for the appropriate shRNA (sh).B:
The 0.1%BSA (negative control), 10% FBS (positive control), and sNF96.2 cells were
used as the chemoattractants for PC3 in amigration assay. The PC3 and sNF96.2 cells
were infected with control lentivirus or lentivirus coding for Sema4D shRNA or
plexin-B1 shRNA, where indicated. C: The 0.1% BSA (negative control), 10% FBS
(positive control), and either wild-type (wt) or Sema4D knockout (KO) DRG were
used as the chemoattractants for PC3, Du-145, or LnCAP cells in an invasion assay.
*P % 0.05. n.s., not significant. D: PC3 cells were transfected with empty vector
control (ctrl) or the myc-tagged chimeric constructs Trk-A/plexin-B1 wild-type
(TrkA-PB1) and Trk-A/plexin-B1 RasGAP mutant (TrkA-PB1 RasGAP mut) and
expression checked in an immunoblot. GAPDHwas used as a loading control in all
immunoblots. E: The 0.1% BSA (BSA, negative control) and NGF, with and without
the ROK inhibitor fasudil, were used as the chemoattractants for PC3 cells expressing
Trk-A/wild-type plexin-B1 chimeric receptors (TrkA-PB1) or chimeras in which the
RasGAP functionwas lost due tomutation (RasGAPmut), in amigration assay. *P%
0.05. F: The 0.1% BSA (negative control) and sNF96.2 cells were used as the
chemoattractants for PC3 cells, control treated or treated with fasudil, in a migration
assay. **P % 0.01.
B
A
C Plexin-B1 shRNA
PC3
C Plexin-B1
LnCAP
0
50
100
150
200
250
300
ctrl shPB1
Nerves
Nerves exhibiting
PNI
195
113
59
15
N
um
be
r o
f n
er
ve
s
*
0
10
20
30
40
50
PB1
overexpression
Nerves
Nerves exhibiting
PNI
43
17
11
1
N
um
be
r o
f n
er
ve
s
*
ctrl
60
Figure 4. Tumor cells expressing plexin-B1 are attracted to nerves in vivo. A:
Tumors derived fromPC3 cells infectedwith a control lentivirus (C) and tumors from
plexin-B1 shRNA-infected cells are shown in hematoxylin-stained sections. More
PNI is seen in tumors derived from control PC3 cells compared with tumors derived
from plexin-B1 shRNA-infected cells. The number of nerves exhibiting PNI per total
nerves counted in xenografts derived from control and plexin-B1 shRNA-infected
PC3 cells is shown in the bar graph. *P% 0.05. B: Tumors derived from LnCAP cells
infected with a control lentivirus (C) or a virus expressing wild-type plexin-B1 are
shown in hematoxylin-stained sections. More PNI is seen in tumors derived from
cells overexpressing plexin-B1 compared with controls. The number of nerves
exhibiting PNI per total nerves counted in xenografts derived from control and
plexin-B1–infected LnCAP are shown in the bar graph. *P % 0.05. Nerves are
highlighted by neurofilament staining in IHC analysis of tumor tissues. Original
magnification, #40 (all panels).
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also show high levels of Sema4D expression (Figure 5A)
when compared with their nontransformed counterparts
(Figure 5A) or tissues from tumors that are not known to
exhibit PNI (Figure 5A), whereas nerve cell lines (Figure
1B) and nerves in tissues (Figure 5B) express plexin-B1.
Quantification of Sema4D expression in neurotropic tu-
mors is shown in Figure 5C and demonstrates that most
HNSCC high-PNI salivary gland tumors (high-grade
MEC, ACC, and PLGA) and prostate cancers studied
exhibited moderate to strong Sema4D expression. To
determine the roles that Sema4D and plexin-B1 play in
the ability of neurotropic tumor cells to induce axonogen-
esis, we examined chemotaxis of the nerve cell line
sNF96.2, infected with control lentivirus or lentivirus-ex-
pressing plexin-B1 shRNA, toward soluble Sema4D and
PC3 cells infected with control lentivirus or lentivirus-
expressing Sema4D shRNA. sNF96.2 cells infected with
plexin-B1 shRNA-expressing lentivirus exhibited reduced
levels of plexin-B1 protein, whereas PC3 infected with
Sema4D shRNA-expressing lentivirus exhibited knock-
down of this protein in an immunoblot, when compared
with control infected cells (Figure 6A). sNF96.2 migrated
toward soluble Sema4D and PC3 cells in an in vitro mi-
gration assay, except when they were expressing lower
levels of plexin-B1, when the PC3 failed to express
Sema4D, or both (Figure 6B). To determine whether
plexin-B1–mediated RhoA activation or R-Ras inactiva-
tion was necessary for formation of dendrites and axonal
processes from nerve cells, we examined sNF96.2 cells.
These cells were transfected with empty vector control or
vectors coding for the chimeric receptors Trk-A, fused to
wild-type plexin-B1 (TrkA-PB1), the RasGAP mutant (TrkA-
PB1 RasGAP mut), or a Trk-A/plexin-B1 construct lacking
the PDZ binding motif necessary for recruiting PDZ-
RhoGEF and leukemia-associated Rho GEF and activating
Rho (TrkA-PB1$PDZ). Then, we treated with NGF while
recording the subsequent morphological changes and
measuring the nerve processes (Figure 6C). Under these
conditions, cells expressing the wild-type construct exhib-
ited formation of elongated neural processes compared
with untreated controls, as did cells expressing the RasGAP
mutant (Figure 6C). Cells expressing the $PDZ mutant did
not show this morphological characteristic (Figure 6C). The
number of cells exhibiting nerve extensions and the total
length of those extensions are shown in the bar graphs
(Figure 6C). These results suggest that formation of nerve
processes is dependent on the ability of plexin-B1 to acti-
vate RhoA and ROK and not on its ability to inactivate
R-Ras.
To further establish biological significance, we cul-
tured DRG from control or plexin-B1 knockout mice33 in
BME, along with PC3 cells, control infected or infected
with lentivirus-expressing Sema4D shRNA, and looked
for outgrowth of neurites. DRG harvested from wild-type
mice exhibited neurite outgrowth when co-cultured with
control-infected PC3 cells, a response greatly attenuated
in DRG from plexin-B1 knockout mice or when using PC3
in which Sema4D levels were reduced by shRNA (Figure
6D). These results are shown graphically in Figure 6E and
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Figure 5. Neurotropic tumors express Sema4D,
whereas nerves express plexin-B1. A: IHC anal-
ysis for Sema4D in normal tissues, tumors not
known to exhibit PNI, or benign controls (low-
PNI tumors/benign controls), and tumors
known for PNI (high-PNI tumors), grouped by
site of origin (mucosa, salivary gland, or pros-
tate). HNSCC, high-grade MEC, ACC, PLGA, and
prostate cancers demonstrate abundant Sema4D
staining. Original magnification, #20. B: Cross
section of a nerve showing expression of plexin-
B1. Original magnification, #20. C: A scale of 0
to 3 was used to assess the number of positively
stained cells; the staining intensity for Sema4D in
the high-PNI tumor groups is shown. These two
scores were added together to yield the ranges
shown in the pie charts.
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strongly suggest that Sema4D produced by tumor cells
would attract nerves in the tumor stroma in vivo.
Sema4D-Producing Tumors Exhibit Enhanced
Nerve Density
If Sema4D, produced by neurotropic tumor cells, en-
hances axonogenesis, then it might be expected that
increased nerve density would be observed in the stroma
surrounding these tumors compared with tumors not ex-
pressing Sema4D. Indeed, we observed more PNI in two
different control HNSCC xenografts versus xenografts of
the same lines with silenced Sema4D; we also observed
more total nerves in controls (Figure 7). These results
are quantified in Table 1, which demonstrates signifi-
cantly higher nerve density, as determined by the num-
ber of nerves per square millimeter, in control HN6 and
HN12 xenografts compared with lines in which
Sema4D was silenced by shRNA. We confirmed these
findings in tumor tissues by staining for the nerve
marker neurofilament. We observed more nerves in the
stroma of high-PNI neurotropic malignancies, such as
ACC, compared with normal control tissues (Figure 8).
An analysis of normal/reactive salivary gland tissue
and low-grade MEC revealed many fewer nerves per
square millimeter when compared with ACC and PLGA
(Table 2). A grouping of epithelial tissues showed that
reactive acanthotic epithelium and basal cell carci-
noma, a low-PNI malignancy, also exhibited a lower
density of nerves compared with HNSCC biopsy spec-
imens (Table 2). Taken together, these results indicate
the phenomenon of cancer-related neurogenesis, as
other groups have shown,34 and suggest that Sema4D
production by neurotropic tumor cells acts through
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Figure 6. Sema4D production by neurotropic malignancies mediates
nerve cell chemotaxis and neurite outgrowth. A: Immunoblot analysis for
Sema4D and plexin-B1 in lysates from PC3 and sNF96.2, respectively,
infected with empty vector control lentivirus (C) or virus coding for the
appropriate shRNA (sh). GAPDH was used as a loading control. B: The
0.1% BSA (negative control), 10% FBS (positive control), soluble Sema4D,
and PC3 cells were used as the chemoattractants for sNF96.2 cells in a
migration assay. sNF96.2 and PC3 cells were infected with control lenti-
virus or lentivirus coding for plexin-B1 shRNA or Sema4D shRNA, where
indicated. C: sNF96.2 cells were transfected with empty vector control
DNA (ctrl) or the chimeric receptors coding for Trk-A/plexin-B1 wild-type
(TrkA-PB1), a RasGAP mutant (TrkA-PB1 RasGAP mut), or a construct
lacking the PDZ binding motif (TrkA-PB1$PDZ), treated with NGF and
examined for nerve processes (neurofilament staining). The number of
cells exhibiting nerve extensions and total length of axons is shown in the
bar graphs. *P % 0.05. D: DRG from wild-type control or plexin-B1
knockout mice were cultured in BME along with PC3 cells, control in-
fected or infected with lentivirus expressing Sema4D shRNA. The white
arrowheads indicate neurite outgrowth at day 3. E: Quantification of
neurite outgrowth to day 11. *P % 0.05.
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Figure 7. Neurotropic tumors exhibit enhanced nerve density in a Sema4D-
dependent manner. Analysis of neurofilament-stained sections of tumor xeno-
grafts composed of control-infected HN6 or HN12 cells (ctrl) or those infected
with Sema4D shRNA-expressing lentivirus (Sema4D shRNA). Sema4D shRNA
tumors exhibit less PNI and far fewer nerves. *P % 0.05, **P % 0.01.
Table 1. Parameters of Tumor Xenografts
Tumor xenograft n
Total area
(mm)2
Nerves
counted
Nerves
(No./mm)2
HN6
Control 4 852 104 0.12
Sema4D shRNA 7 202 11 0.06
HN12
Control 4 148 35 0.24
Sema4D shRNA 5 138 15 0.11
The total number of samples, tumor area, nerves, and nerves per
square millimeter in tumor xenografts composed of control-infected HN6
and HN12 cells or cells infected with lentiviruses expressing Sema4D
shRNA from Figure 7.
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plexin-B1 on nerves to mediate this effect, which then
plays a role in promoting PNI.
Discussion
PNI is a tropism of malignant tumor cells for nerve bun-
dles in the surrounding tissues, defined as the presence
of malignant cells in the perineural space with total or
near-total circumferential involvement of the nerve in tan-
gential histopathological sections.35 PNI is a form of tu-
mor spread that hinders the ability to establish local con-
trol of a malignancy because neoplastic cells can spread
along nerve tracts far from the primary lesion and are
often missed during surgery. As a result, PNI is an inde-
pendent prognostic factor for many human carcinomas,
such as prostate,27 pancreatic,36 colorectal,37 salivary
gland,4 and HNSCC.38 cDNA microarrays used to profile
gene expression in ACC have identified dysregulation of
numerous genes associated with the cell cycle, the cy-
toskeleton, and extracellular matrix binding, which influ-
ence the production of neurotropic factors and adhesion
molecules that could contribute to PNI.39 We have previ-
ously shown that production of Sema4D by some tumors
attracts plexin-B1–expressing endothelial cells in a RhoA
and ROK-dependent manner, a process co-opted by
malignancies to induce blood vessel growth into a tu-
mor.21 Therefore, we postulated that, because some ma-
lignancies also express high levels of plexin-B1, perhaps
the tumor cells might be attracted to nerves, which are
known sources of Sema4D. Indeed, prostate tumors,
which invade along local peripheral nerves, have dem-
onstrated overexpression of plexin-B1 in cancer devel-
opment and progression.40 We observed that plexin-B1
is highly expressed in neurotropic malignancies and cell
lines but less so in healthy controls or in cell lines and
tissues from malignancies that are not known to exhibit
much PNI, whereas Sema4D is expressed in nerves.
Through the use of RNAi, chimeric receptor constructs,
and inhibitory compounds, our studies illustrate a model
in which Sema4D acts as a chemoattractant for malig-
nancies that promote PNI.
Interestingly, we also observed that nerve cells are
stimulated to migrate and form dendritic projections to-
ward neurotropic tumors using the same system of sig-
naling proteins, findings that support the theory that PNI
also may result from tumor-mediated stimulation of ax-
onogenesis or neurogenesis. Although semaphorins and
plexins have mostly been associated with axonal guid-
ance as repulsive signals, some semaphorin-plexin inter-
actions actually enhance nerve growth. Prostate cancers
have exhibited increased nerve density as a result of
production of Sema4F by the tumors,34 whereas there are
also reports that, depending on the context, Sema4D can
act as an attractive signal for neurite and axon
growth.41,42 In one study43 focusing on how Sema4D and
plexin-B1 modulate axonal trajectories and dendritic mor-
phological characteristics in neurons over time, the au-
thors show that Sema4D increases the complexity and
arborization of developing neurites in hippocampal neu-
rons by activating plexin-B1. Such a phenomenon may
be at work in our system because this effect required
activation of the RhoA-ROK pathway, which we demon-
strated herein, and the receptor tyrosine kinase phospha-
tidylinositol 3-kinase pathway, identical to the mechanism
of plexin-B1 signaling we have previously observed in
endothelial cells exhibiting a pro-angiogenic phenotype
in the presence of Sema4D.28,32
Sema4D is expressed on the surface of cells as a
homodimer, but it has also been shed into the surround-
ing environment through proteolytic cleavage, allowing it
to work at a distance.44,45 This is important in availability
of Sema4D and also for its function, because membrane-
bound and cleaved forms of different semaphorins have
exhibited somewhat opposing effects on their target tis-
sues. For example, invertebrate transmembrane sema1a
is a chemoattractant in axon pathfinding in vivo, whereas
its soluble form acts as a repulsive factor.46 Sema4D also
has exhibited a dual role. The transmembrane form is
known to repel growing axons,47 but the soluble, extra-
cellular portion promotes neurite outgrowth in PC12 cells
and axon outgrowth in DRG.48 In general, bifunctionality
of the semaphorins is not unusual, with Sema3A, E, and C
attracting or repelling axons and dendrites, depending
on the form, experimental system, and cell type
used.41,48,49
Because we show that both Sema4D and plexin-B1 are
expressed in neurotropic malignancies, it is plausible that
autocrine or paracrine signaling involving these proteins
exists in neurotropic tumor cells that influence PNI. How-
ever, we believe the data do not support such a mecha-
ACC Salivary gland
Figure 8. IHC stain for neurofilament in ACC compared with normal salivary
gland tissue. Original magnification, #20. ACC shows higher nerve density.
Table 2. Parameters of Tissue Biopsy Specimens
Tissue n
Total area
(mm2)
Nerves
counted
Nerves
(No./mm2)
Salivary gland
Mucocele 9 1050.5 49 0.05
LG MEC 12 865.5 52 0.06
ACC 7 1053.1 158 0.15
PLGA 5 1298.2 182 0.14
Epithelial
Acanthosis 8 276.4 36 0.13
BCC 8 335.1 33 0.10
HNSCC 6 333.7 103 0.31
Quantification of nerve density in neurofilament-stained biopsy spec-
imens of a salivary gland group, consisting of the high-PNI malignancies,
ACC and PLGA, compared with the low-PNI malignancy, LG MEC, and
normal/ reactive gland (mucocele) and an epithelial group, composed of
HNSCC compared with BCC and normal/reactive mucosa (acanthosis).
LG, low grade.
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nism. We used RNAi for Sema4D and plexin-B1 and
tissues from knockout mice to show that high-PNI tumor
cells exhibit chemotaxis to nerve cells and whole nerve
tissues but fail to do so when those nerve cell lines or
tissues do not express Sema4D. This happens even
when the tumor cells themselves still express both
Sema4D and plexin-B1 and the autocrine or paracrine
mechanism would presumably be intact. There is also the
possibility that Sema4D–plexin-B1–mediated promotion
of PNI represents just one facet of tumor aggressiveness,
and that tumors expressing both of these proteins might
exhibit enhanced invasive behavior in general, as sug-
gested by Casazza et al 50 for Sema3E and plexin-D1.
There would seem to be evidence in the literature to
support the idea that Sema4D and plexin-B1 promote
metastasis and aggressive growth, but it is not consistent
and there are even studies that demonstrate the oppo-
site. Rody et al51,52 have shown that the presence of
plexin-B1 in estrogen receptor–positive breast tumors
correlates with a favorable prognosis, and other
groups53 have shown that plexin-B1 behaves as a tu-
mor suppressor in melanoma. There is a great deal of
evidence that PNI is a specific pathological phenome-
non distinct from other aspects of tumor aggressive-
ness. Some tumor types exhibit characteristic neural
invasion, whereas other, more aggressive, tumors fail
to do so even at advanced stages. Therefore, it is likely
that the particular set of conditions or genetic back-
ground necessary for a tumor cell to acquire the ability
to invade nerves is different from other aspects of
tumor invasion, such as the ability to metastasize. For
example, the microcystic adnexal carcinoma, a rare
tumor of the midface in middle-aged women, is a lo-
cally aggressive malignancy known to infiltrate muscle
and show PNI, but it hardly ever metastasizes.54 High-
grade MEC, on the other hand, behaves locally in a
similar manner (infiltrative growth and PNI) but does
exhibit metastasis. Even for well-studied semaphorin-
plexin pairs, local tumor growth and distant spread are
separable events.50
PNI likely involves a complex interaction between
nerve and cancer cells, similar to the signals ex-
changed between nerves, stromal cells, and epithe-
lium during development and regeneration in response
to injury, with the semaphorins, plexins, and other fac-
tors, both membrane bound and secreted, essentially
generating a microenvironment in which tumor and
nerve cells grow toward each other.27 Combined with
the role they play in tumor-induced angiogenesis, it
could explain why up-regulation of Sema4D and
plexin-B1 in prostate cancer,40 breast cancer,55 and
some sarcomas56 contributes to such a poor progno-
sis. Deciphering the mechanisms of PNI will lend in-
sight into the biological characteristics of tumor-stroma
interactions and have wide-ranging effects on the abil-
ity to control cancers, such as prostate and pancreatic
cancers, HNSCC, and salivary gland tumors, helping
to alleviate the pain and significant morbidity associ-
ated with these neurotropic malignancies.
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